FGFR2 and metabolic dysfunction-associated steatohepatitis: Our previous study showed that VC pretreatment might be a new treatment method of NAFLD/NASH through attenuate hepatocyte stress induced by TNFα via activation of the FGF21/FGFR2/adiponectin pathway (24).